Evidence map›Paper›PMID 36843221›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2023

Degradable Bottlebrush Polypeptides and the Impact of their Architecture on Cell Uptake, Pharmacokinetics, and Biodistribution In Vivo.

Paul Strasser, Bianca Montsch, Silvia Weiss, Haider Sami, Christoph Kugler, Sonja Hager, Hemma Schueffl, Robert Mader, Oliver Brüggemann, Christian R Kowol and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Advanced Macromolecular Architectures via Inorganic Polymers.Macromolecular rapid communications · 2026
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Paul StrasserInstitute of Polymer Chemistry, Johannes Kepler University Linz, Linz, 4040, Austria.ORCID 0000-0001-9331-6570
Bianca MontschCenter for Cancer Research and Comprehensive Cancer Center, Medical University Vienna, Vienna, 1090, Austria.ORCID 0000-0002-5513-5258
Silvia WeissLaboratory of Macromolecular Cancer Therapeutics (MMCT), Department of Pharmaceutical Sciences, Faculty of Life Sciences, University of Vienna, Vienna, 1090, Austria.ORCID 0000-0001-6741-3211
Haider SamiLaboratory of Macromolecular Cancer Therapeutics (MMCT), Department of Pharmaceutical Sciences, Faculty of Life Sciences, University of Vienna, Vienna, 1090, Austria.ORCID 0000-0002-5777-3472
Christoph KuglerLaboratory of Macromolecular Cancer Therapeutics (MMCT), Department of Pharmaceutical Sciences, Faculty of Life Sciences, University of Vienna, Vienna, 1090, Austria.ORCID 0000-0002-6503-7731
Sonja HagerCenter for Cancer Research and Comprehensive Cancer Center, Medical University Vienna, Vienna, 1090, Austria.ORCID 0000-0001-8221-1044
Hemma SchuefflCenter for Cancer Research and Comprehensive Cancer Center, Medical University Vienna, Vienna, 1090, Austria.ORCID 0000-0002-9959-9716
Robert MaderDepartment of Medicine I, Medical University of Vienna, Vienna, 1090, Austria.ORCID 0000-0003-3017-8240
Oliver BrüggemannInstitute of Polymer Chemistry, Johannes Kepler University Linz, Linz, 4040, Austria.
Christian R KowolResearch Cluster "Translational Cancer Therapy Research", University of Vienna, Vienna, 1090, Austria.ORCID 0000-0002-8311-1632
Manfred OgrisLaboratory of Macromolecular Cancer Therapeutics (MMCT), Department of Pharmaceutical Sciences, Faculty of Life Sciences, University of Vienna, Vienna, 1090, Austria.ORCID 0000-0002-4576-6961
Petra HeffeterCenter for Cancer Research and Comprehensive Cancer Center, Medical University Vienna, Vienna, 1090, Austria.ORCID 0000-0001-6401-8646
Ian TeasdaleInstitute of Polymer Chemistry, Johannes Kepler University Linz, Linz, 4040, Austria.ORCID 0000-0001-5953-9084
University of Vienna · ATJohannes Kepler University of Linz · ATMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bottlebrush polymers are highly promising as unimolecular nanomedicines due to their unique control over the critical parameters of size, shape and chemical function. However, since they are prepared from biopersistent carbon backbones, most known bottlebrush polymers are non-degradable and thus unsuitable for systemic therapeutic administration. Herein, we report the design and synthesis of novel poly(organo)phosphazene-g-poly(α-glutamate) (PPz-g-PGA) bottlebrush polymers with exceptional control over their structure and molecular dimensions (Dh ≈ 15-50 nm). These single macromolecules show outstanding aqueous solubility, ultra-high multivalency and biodegradability, making them ideal as nanomedicines. While well-established in polymer therapeutics, it has hitherto not been possible to prepare defined single macromolecules of PGA in these nanosized dimensions. A direct correlation was observed between the macromolecular dimensions of the bottlebrush polymers and their intracellular uptake in CT26 colon cancer cells. Furthermore, the bottlebrush macromolecular structure visibly enhanced the pharmacokinetics by reducing renal clearance and extending plasma half-lives. Real-time analysis of the biodistribution dynamics showed architecture-driven organ distribution and enhanced tumor accumulation. This work, therefore, introduces a robust, controlled synthesis route to bottlebrush polypeptides, overcoming limitations of current polymer-based nanomedicines and, in doing so, offers valuable insights into the influence of architecture on the in vivo performance of nanomedicines.

Indexed as

PolymersWaterMacromolecular SubstancesPeptidesTissue DistributionMacromolecular SubstancesPeptidesPolymersWaterbiodistributionbottlebrush polymersnanomedicinepharmacokineticspolyglutamatepolymer therapeuticspolyphosphazenes

Identifiers

PMID36843221
PMCPMC11475343
OpenAlexW4322217224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.